Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangkui Capsules are a Chinese Patent Medicine (CPM) derived from the ethanol extract of the flowers of *Abelmoschus manihot* (L.) Medic. It is widely used in China for the treatment of various kidney diseases, particularly chronic kidney disease (CKD) and diabetic kidney disease (DKD). The drug's therapeutic effects are primarily attributed to its ability to reduce proteinuria and protect renal function through anti-inflammatory, antioxidant, and anti-fibrotic pathways. It contains several active flavonoids, such as rutin, hyperoside, and myricetin. Clinical studies have demonstrated its efficacy as an adjunctive therapy to standard treatments like ACE inhibitors or ARBs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangkui Capsules.